RecruitingNot ApplicableNCT04446442

Cerebellar tDCS in Children With Autism Spectrum Disorder

Biologic Effects and Efficacy of Cerebellar tDCS in Children With Autism Spectrum Disorder


Sponsor

University of Texas Southwestern Medical Center

Enrollment

60 participants

Start Date

Jun 4, 2019

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this research study is to investigate whether tDCS to the cerebellum (specifically, the right crus I/II area of the cerebellum) of children and young adults with autism spectrum disorders (ASD) is safe and to examine its effects on some of the symptoms of ASD, such as repetitive behaviors and hyperactivity.


Eligibility

Min Age: 4 YearsMax Age: 17 Years

Inclusion Criteria4

  • -17 years old
  • Diagnosed with ASD and ADOS-2
  • IQ Score no less than 70 (1.5 Standard Deviations below the mean)
  • Language Level (Speech consists of, at minimum, flexible, spontaneous, simple, sentences)

Exclusion Criteria5

  • Brain implants, metal implants, pacemakers, or biomedical devices
  • Diagnosis of epilepsy
  • Hearing or visual impairments
  • History of brain injury
  • Known brain abnormalities not associated with ASD

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEtDCS

A current of 1 mA will be administered for 20 minutes of with either anodal or cathodal tDCS administration to the right crus I/II area of the cerebellum.


Locations(2)

Children's Medical Center

Dallas, Texas, United States

University of Texas Southwestern

Dallas, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04446442


Related Trials